Download Files:
Products Details
Product Description
– Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B)[1].
Web ID
– HY-144067
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C26H23F2N3O7
References
– [1]Shuhui Chen, et al. Fused ring derivatives and their pharmaceutical applications. Patent WO2021233302A1.
CAS Number
– 2741952-36-1
Molecular Weight
– 527.47
SMILES
– CN1[C@]2([H])N(N3C(C1=O)=C(C(C=C3)=O)OCOC(OC)=O)[C@](C4=CC=CC=C4)([H])C5=CC(F)=C(F)C=C5OCC2
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– Influenza Virus
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
